Blair William & CO Actinium Pharmaceuticals, Inc. Transaction History

Blair William & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$7.05 - $14.41 $102,690 - $209,896	-14,566 Reduced 14.01%	89,400 $952,000
Q3 2022 Nov 09, 2022	BUY	$4.81 - $8.48 $28,859 - $50,880	6,000 Added 6.12%	103,966 $767,000
Q2 2022 Aug 10, 2022	SELL	$4.71 - $7.11 $12,246 - $18,486	-2,600 Reduced 2.59%	97,966 $471,000
Q1 2022 May 13, 2022	BUY	$4.57 - $6.4 $62,609 - $87,680	13,700 Added 15.77%	100,566 $514,000
Q4 2021 Feb 14, 2022	BUY	$6.01 - $8.8 $27,045 - $39,600	4,500 Added 5.46%	86,866 $522,000
Q3 2021 Nov 12, 2021	BUY	$5.76 - $9.67 $177,984 - $298,803	30,900 Added 60.04%	82,366 $730,000
Q2 2021 Aug 12, 2021	BUY	$7.01 - $8.63 $117,067 - $144,121	16,700 Added 48.04%	51,466 $407,000
Q1 2021 May 13, 2021	BUY	$7.62 - $9.79 $264,916 - $340,359	34,766 New	34,766 $265,000

8.35M

65.2K

21.7K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $33.5M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.